A naturally occurring thymic peptide that promotes T-cell maturation and dendritic cell function, acting substantially through Toll-like receptor signalling. It shifts immune responses toward Th1 and augments antigen presentation. Unlike most peptides in this library, its mechanism is comparatively well characterised.
Studied in chronic hepatitis B and C, as a vaccine adjuvant, in sepsis, and in cancer immunotherapy contexts. Trial results are mixed but the human evidence base is real and substantially larger than for the grey-market peptides.
Not FDA-approved. Approved and marketed in roughly 30 other countries (as Zadaxin) for hepatitis B and C and as a vaccine adjuvant. Was subject to FDA 503A bulk substance review.
Generally well tolerated in trials. Immunostimulation carries theoretical concerns in autoimmune disease and transplant recipients.
Forge Bioenergy does not publish dosing, reconstitution, or administration protocols for any peptide. See our editorial policy for why. If you are considering any substance on this page, that conversation belongs with a licensed physician.
Regulatory status changes. This page reflects our reading of public sources as of July 2026 and should be independently verified before it is relied upon.